Zagreb, Croatia

Mislav Orsulic

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2016-2019

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Mislav Orsulic: Innovator in Pharmaceutical Compositions

Introduction

Mislav Orsulic is a notable inventor based in Zagreb, Croatia. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of inflammatory disorders. With a total of 2 patents, his work is paving the way for advancements in medical treatments.

Latest Patents

Orsulic's latest patents focus on compounds and pharmaceutical compositions for the treatment of inflammatory disorders. These inventions disclose compounds according to a specific formula, which are designed to inhibit JAK. The compounds may be utilized in pharmaceutical compositions for preventing and treating various conditions in mammals, including humans. These conditions encompass allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, and diseases associated with hypersecretion of IL6 or interferons.

Career Highlights

Mislav Orsulic is currently associated with Galapagos NV, where he continues to innovate in the pharmaceutical sector. His work is characterized by a commitment to developing effective treatments for complex medical conditions.

Collaborations

Orsulic collaborates with esteemed colleagues such as Christel Jeanne Marie Menet and Oscar Mammoliti. Their combined expertise contributes to the advancement of pharmaceutical research and development.

Conclusion

Mislav Orsulic's contributions to the field of pharmaceuticals are noteworthy, particularly in the area of inflammatory disorder treatments. His innovative patents and collaborations highlight his dedication to improving health outcomes through scientific advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…